PrEP use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association.

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

(HealthDay News) — Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association. Laura M. Mann ...

July 23, 2024 — Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global ...

In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...

In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.

While annual HIV surveillance reports released by the CDC in May showed that the number of estimated new HIV infections per ...

This initiative is part of the Ministry's commitment to broaden health services, enhance HIV prevention, and combat sexually transmitted diseases. Dr. Fahad Al-Ghamlas, the Director of the Public ...

Ireland based pharmaceutical company Gilead Sciences has said it will grant licences to six generic manufacturers to produce low cost lenacapavir, which has shown unprecedented efficacy at preventing ...